Ardena Expands with Acquisition of Catalent's Drug Manufacturing Site

Ardena, a focused pharmaceutical Contract Development and Manufacturing Organization (CDMO) and bioanalytical Contract Research Organization (CRO) operating in Belgium, Spain, the Netherlands, and Sweden, has finalized its acquisition of Catalent’s drug product manufacturing site located in Somerset, New Jersey.

This acquisition represents a key achievement in Ardena’s strategic growth in North America, enhancing its abilities in late-stage and small-scale commercial production of oral drug products while further uniting its extensive range of drug development services.

The Somerset, NJ facility spans more than 50,000 sq ft of cGMP manufacturing area and is occupied by over 200 talented scientists and technicians. It is an acknowledged Center of Excellence for sophisticated oral dosage forms, focusing on modified-release formulations, Hot Melt Extrusion for improved bioavailability, and the management of controlled substances.

These abilities enhance Ardena's current skills in Europe, allowing for the provision of customized solutions to pharmaceutical and biotechnology firms globally. Moreover, Ardena is broadening its Bioanalytical Services in North America with the launch of a new bioanalytical laboratory at the Somerset site.

The forthcoming investment will feature a new lab of over 2,500 sq ft, projected to begin operations by Q3 2025, offering sophisticated analytical testing services for small and large molecules, reflecting Ardena’s European expertise in immunochemistry, LC-MS/MS, flow cytometry, and qPCR technologies. This new laboratory will offer improved assistance for worldwide clinical trial initiatives.